N/A N=14 Fresh Versus Old Red Blood Cells for Transfusion
Iron, Abnormal Blood Level · Other Abnormal Blood Chemistry
Primary: Measure of Non-transferrin-bound Iron — 0.16; 3.17 μM
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=5 Transfusion of Biotinylated Red Blood Cells
Anemia
Primary: Number of Participants That Had bRBC Detectable at 70 Days Post-intervention — 5 participants
N/A N=60 Duration of Red Blood Cell Storage Prior to Transfusion
Iron, Blood Level Abnormal
Primary: Non-transferrin-bound Iron Level (AUC) — 0.5588; 2.839; 3.684; 5.272 microMole*hr/L
N/A N=223 Bloodsafe Ghana- Iron and Nutritional Counseling Strategy Pilot Study
Iron-deficiency Anemia · Iron-deficiency
Primary: Haemoglobin Level — 11.35; 12.28 g/dL — p=0.025
Phase 3 N=4,994 Standard Issue Transfusion Versus Fresher Red Blood Cell Use in Intensive Care- A Randomised Controlled Trial
Transfusion · Age of Blood
Primary: Mortality at Day 90 — 610; 594; 264; 259 participants
Phase 1 N=29 Inactivation of Whole Blood With Mirasol
Focus of Study: Radiolabel Recovery and Survival of RBCs
Primary: Red Blood Cell (RBC) 24-Hour Recovery — 82.51; 91.70 % 24-hour RBC Recovery
Phase 1 N=170 Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive Solution
Blood Donors
Primary: Red Blood Cell Post-filtration Recovery — 92.57; 92.70; 90.96; 90.23 % recovery at day 0
N/A N=722 Balancing Risk: Red Blood Cell Transfusion Strategies In Cardiac Surgery
Anemia
Primary: A Composite of In-hospital Postoperative Morbidity and Mortality — 59; 68 Participants
Phase 3 N=26 Age of Blood in Sickle Cell Transfusion
Sickle Cell Disease
Primary: Proportion of Biochemically Old Red Cell Units — 0.71; 0.86 proportion biologically old units — p=0.051
Phase 3 N=1,538 Age of Blood in Children in Pediatric Intensive Care Units
Anemia
Primary: Number of Participants With New or Progressive Multiple Organ Dysfunction Syndrome (NPMODS) — 147; 133 Participants
Phase 3 N=55 Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.
Meningitis, Meningococcal, Serogroup B
Primary: Number of Subjects Reporting Unsolicited Adverse Events (AEs). — 0; 0; 0; 0 Subjects
N/A N=254 Frozen Red Blood Cell Transfusions in Trauma Patients
Blood Loss · Anemia · Trauma
Primary: Tissue Oxygenation — 100.3; 98.2; 98.3 percentage of baseline
Phase 2 N=104 Red Blood Cell (RBC) Survival Following Transfusion in Infants
Neonatal Anemia
Primary: Number of Discrete Biotinylated RBC Densities (up to 5 Discrete Densities) That Can be Accurately Measured by Flow Cytometry, i.e., Without Overlap. — 5; 5 flow…
N/A N=49 Comparison Between Return and Wastage of Your Own Blood, Collected During Spinal Surgery, for Verification of Safety When Returning Blood
Spinal Surgery
Primary: Difference in Plasma Free Hemoglobin (p-Hb) Concentration — 0.1; 0.0 g/l — p=0.6294
Phase 2 N=100 Clinical Investigation to Evaluate the Hemanext® Oxygen Reduction System - Pivotal Trial
Whole Blood Donation and Leukoreduction
Primary: % of Red Blood Cells With Hemolysis — 0.29; 0.29 % of Red Blood Cells with Hemolysis
N/A N=22 Survival and Recovery of Radio-labeled Platelets Derived From Mirasol-treated Whole Blood
Blood Safety
Primary: Platelet 24-hour Relative Recovery — 43.31; 52.01 Percentage of platelet count
N/A N=227 Clinical and Biological Efficacy of Mirasol-treated Fresh Whole Blood for the Prevention of Transfusion-transmitted Malaria
Malaria
Primary: Percentage of Participants With Incidence of Transfusion-transmitted Malaria — 3.6; 21.6 Percentage of participants
Phase 2 N=43 Adverse Effects of Red Blood Cell Transfusions: A Unifying Hypothesis (Aim 3)
Cardiovascular Diseases
Primary: Brachial Artery Flow-mediated Dilation (FMD) After Fresh Red Blood Cells (RBCs) Transfusions vs. Storage-aged Red Blood Cells (saRBCs) Transfusions at Baseline — 4.87…
Phase 2 N=17 Adverse Effects of RBC Transfusions: A Unifying Hypothesis
Healthy Volunteers
Primary: The Effects of Storage-related RBC Changes on Acetylcholine-stimulated (NO-mediated) Forearm Blood Flow. — 19.02; 18.42; 17.61; 22.89 mL / 100 mL / min
N/A N=45 A Clinical Study to Investigate if Transfusion of Patients Own Shed Blood Improves the Immunological Status in Comparison to Transfusion of Donor Blood ("Bank Blood")
Arthroplasty, Replacement, Knee · Blood Transfusion, Autologous · Blood Transfusion
Primary: Frequency of Natural Killer Cells as Measured With Flow Cytometry. — 2.98; 2.26 total number of cells * 10^5/mL
N/A N=177 Microparticles in Stored RBC as Potential Mediators of Transfusion Complications
Coronary Artery Bypass
Primary: In Hospital Mortality — 0; 4 participants — p=0.142
Phase 3 N=581 Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients
Anemia
Primary: Percentage of Patients Who Have Received at Least One Study Transfusion With a Diagnosis of Renal Impairment Defined as: — 46; 45 Participants
Phase 1 N=22 Biotin-RBC Transfusion in SCD
Sickle Cell Disease
Primary: Percentage of Biotin Labeled RBCs — 97.3; 80; 21 percentage of biotin-labeled RBCs
Phase 4 N=107 Early Whole Blood in Patients Requiring Transfusion After Major Trauma
Trauma/Injury Problem
Primary: Units of Blood Products Required During the First 24 Hours After Emergency Department Admission — 12; 13 units of blood
N/A N=79 Donor Iron Deficiency Study - Red Blood Cells From Iron-deficient Donors: Recovery and Storage Quality
Iron Deficiency
Primary: 51-Chromium 24-hour Post-transfusion RBC Recovery of Units — 1.6; -0.4 percentage change
N/A N=62 Clinical Investigation to Evaluate the Haemonetics POLFA Modified Sample Needle Assembly With Vacuum Tube Holder
Transmission, Blood, Recipient/Donor
Primary: Plasma Supernatant Hemoglobin — 26.8; 28.0 mg/dL
Phase 3 N=199 Low-Titer O Positive Whole Blood Versus Component Therapy for Emergent Transfusion in Trauma Patients
Hemorrhagic Shock · Acute Blood Loss Anemia · Traumatic Brain Injury
Primary: Packed Red Blood Cells Equivalents Units Transfused (1 Whole Blood Unit Treated as 1 Packed Red Blood Cell Unit and 1 Fresh Frozen Plasma Unit) — 3.8; 5.7 units
Phase 4 N=20 Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding
Hypofibrinogenemia · Bleeding
Primary: Total Number of RBCs Used Over Admission — 5.8; 6.7 RBC Units
N/A N=22 Hypoxic Red Blood Cells for Burns and Hematological Malignancies at Haukeland University Hospital
Hematologic Neoplasms · Burns
Primary: Number of Participants Who Experienced an Adverse Event (All Types/Grades) Within a Time Frame up to 24 Hours Following the Transfusion. — 2; 3 Participants
Phase 2 N=60 Transfusion Strategies in Pediatric Cardiothoracic Surgery
Congenital Heart Disease
Primary: Mean Arterial Lactate Level — 1.4; 1.4 mmol/L